1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B‐cell lymphomas
    Meeting Abstract

    Jagadeesh, D.; Horwitz, S.; Bartlett, N. L.; Advani, R.; Jacobsen, E.; Duvic, M.; Gautman, A.; Rao, S.; Onsum, M.; Fanale, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step‐up dosing of mosunetuzumab in relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL)
    Meeting Abstract

    Sehn, L. H.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Diefenbach, C. M.; Flinn, I.; Hong, J. Y.; Kim, W. S.; Matasar, M.; Nastoupil, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical significance and outcomes in patients with diffuse large B‐cell lymphoma (DLBCL) harboring extra copies [EC] and/or translocations [TL] of MYC, BCL2, and BCL6
    Meeting Abstract

    Sermer, D.; Bobillo, S.; Seshan, V.; Dogan, A.; Younes, A.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in TRANSCEND NHL 001
    Meeting Abstract

    Wang, M.; Gordon, L. I.; Palomba, M. L.; Abramson, J. S.; Andreadis, C.; Ghosh, N.; Lunning, M.; Maloney, D.; Farazi, T.; Garcia, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Response to A+CHP by CD30 expression in the ECHELON‐2 trial
    Meeting Abstract

    Illidge, T.; Horwitz, S.; Iyer, S.; Bartlett, N.; Kim, W.; Tilly, H.; Belada, D.; Feldman, T.; Illés, Á; Jacobsen, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis in the PH 3 ECHELON‐1 study: Worse outcome with ABVD in patients with elevated baseline levels of SCD30 and TARC
    Meeting Abstract

    Radford, J.; Connors, J. M.; Younes, A.; Gallamini, A.; Ansell, S. M.; Kim, W. S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Anaplastic large cell lymphoma, ALK‐negative: Analysis of 235 cases collected by the T‐cell project
    Meeting Abstract

    Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y. H.; Manni, M.; Horwitz, S. M.; Antonio De Souza, C.; Radford, J.; Varela, S. B.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (PTS) with CD30‐positive (CD30+) cutaneous T‐cell lymphoma (CTCL)
    Meeting Abstract

    Horwitz, S. M.; Scarisbrick, J.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II‐IV peripheral T‐cell lymphoma: Phase II results
    Meeting Abstract

    Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save